USCOM LIMITED — Regulatory Filings 2020

Feb 5, 2020

==> picture [48 x 57] intentionally omitted <==

5 February 2020

Mr Corey Lian Adviser, Listings Compliance (Sydney) Australian Securities Exchange 20 Bridge Street Sydney NSW 2000

Dear Mr Lian

Price query

I refer to your letter dated 5 February 2020 regarding the change in the price and the increase in volume of trading in Uscom’s shares. The following information is provided in response to your request.

1. No.

2. Not applicable.

3. The Company notes that there is speculation in online investment forums regarding the applicability of the Uscom 1A device in the monitoring of coronavirus patients in China. The Uscom 1A device accounts for 75% of the Company’s sales, with 62% of all sales occurring in China/Asia. The device was originally fast-tracked for approval in China due to its potential importance in the management of Severe Acute Respiratory Syndrome (SARS), an illness caused by a coronavirus. The Uscom 1A device has since been widely adopted for the management and monitoring of infectious diseases in ICU’s in China and other parts of the world, and it recently received a five-year extension of its regulatory certification from the China National Medical Products Administration (see Uscom ASX announcement 6 January 2020). While Uscom has a long-established presence in China, and is well positioned with regard to the Uscom 1A device and its use in hospitals in China, it cannot provide any further information as to the direct impact of coronavirus on sales of Uscom 1A at this time.

4. Uscom is complying with the listing rules and, in particular, listing rule 3.1.

5. The above responses have been approved by Brett Crowley who has delegated authority from the board to respond to ASX on disclosure matters.

Yours faithfully

==> picture [84 x 48] intentionally omitted <==

Brett Crowley Director

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66-74 Clarence Street, Sydney NSW 2000 T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

==> picture [455 x 5] intentionally omitted <==

==> picture [33 x 50] intentionally omitted <==

5 February 2020 Reference: 13559

Mr Brett Crowley Company Secretary Uscom Limited Suite 1, Level 7, 10 Loftus Street, Sydney, NSW, 2000

By email:

Dear Mr Crowley

USCOM Ltd (‘UCM’): Price Query

We note the change in the price of UCM’s securities from a low of $0.17 to a low of $0.27 today.

We also note the significant increase in the volume of UCM’s securities traded from 4 February 2020 to 5 February 2020.

Request for Information

In light of this, ASX asks UCM to respond separately to each of the following questions and requests for information:

1. Is UCM aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

2. If the answer to question 1 is “yes”.

3. (a) Is UCM relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in UCM’s securities would suggest to ASX that such information may have ceased to be confidential and therefore UCM may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is “yes”, you need to contact us immediately to discuss the situation.

4. (b) Can an announcement be made immediately? Please note, if the answer to this question is “no”, you need to contact us immediately to discuss requesting a trading halt (see below).

5. (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?

6. If the answer to question 1 is “no”, is there any other explanation that UCM may have for the recent trading in its securities?

7. Please confirm that UCM is complying with the Listing Rules and, in particular, Listing Rule 3.1.

8. Please confirm that UCM’s responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of UCM with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than 9:30 AM AEDT tomorrow Thursday, 6 February 2020 . If we do not have your

ASX Customer Service Centre 131 279 | asx.com.au

ASX Limited [[Listings]]

==> picture [455 x 5] intentionally omitted <==

response by then, ASX will likely suspend trading in UCM’s securities under Listing Rule 17.3. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, UCM’s obligation is to disclose the information “immediately”. This may require the information to be disclosed before the deadline set out in the previous paragraph.

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market. Your response should be sent to me by e-mail at ListingsComplianceSydney@asx.com.au . It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Listing Rules 3.1 and 3.1A

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity’s securities. Exceptions to this requirement are set out in Listing Rule 3.1A. In responding to this letter, you should have regard to UCM’s obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B . It should be noted that UCM’s obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is “yes” and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in UCM’s securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

• the reasons for the trading halt;

• how long you want the trading halt to last;

• the event you expect to happen that will end the trading halt;

• that you are not aware of any reason why the trading halt should not be granted; and

• any other information necessary to inform the market about the trading halt, or that we ask for.

We may require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 Trading Halts & Voluntary Suspensions .

Suspension

If you are unable to respond to this letter by the time specified above ASX will likely suspend trading in UCM’s securities under Listing Rule 17.3.

Enquiries

If you have any queries or concerns about any of the above, please contact me immediately.

2/3 ASX Customer Service Centre 131 279 | asx.com.au

==> picture [455 x 5] intentionally omitted <==

Kind regards

Corey Lian

Adviser, Listings Compliance (Sydney)

3/3 ASX Customer Service Centre 131 279 | asx.com.au